IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced abstracts for three poster presentations at AACR Annual Meeting, April 17-22, 2026 in San Diego. Presentations cover preclinical data for IDE034 (PTK7/B7-H3 TOP1 bispecific ADC), IDE574 (KAT6/7 inhibitor) and IDE892 (PRMT5 inhibitor).

Each program is in Phase 1 clinical study evaluating safety, tolerability, PK and efficacy across large solid tumors. Poster details include dates, session titles, poster numbers and availability on the company website after the meeting.

News Market Reaction – IDYA

-2.80%

1 alert

-2.80% News Effect

On the day this news was published, IDYA declined 2.80%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Number of posters: 3 poster presentations AACR meeting dates: April 17–22, 2026 IDE034 poster number: 232 +5 more

8 metrics

Number of posters 3 poster presentations AACR Annual Meeting 2026

AACR meeting dates April 17–22, 2026 AACR Annual Meeting in San Diego

IDE034 poster number 232 DNA Damage and Repair 1 session

IDE034 session time April 19, 2026, 2:00–5:00 pm PDT AACR 2026 poster session

IDE574 poster number 4483 Epigenetic Modulators 1 session

IDE892 poster number 4505 Epigenetic Modulators 1 session

Current price $34.27 Prior to AACR abstracts news

52-week range $13.45 – $39.28 52-week low and high before news

Market Reality Check

Price: $32.75 Vol: Volume 957,929 is 1.13x t...

normal vol

$32.75 Last Close

Volume Volume 957,929 is 1.13x the 20-day average of 845,171 shares. normal

Technical Shares at $34.27 are trading above the 200-day MA of $28.85 and 12.75% below the 52-week high of $39.28.

Peers on Argus

IDYA fell 1.49% while peers were mixed: DNLI +0.88%, GLPG +1.68%, BLTE -2.18%, F...

IDYA fell 1.49% while peers were mixed: DNLI +0.88%, GLPG +1.68%, BLTE -2.18%, FOLD -0.07%, TVTX -1.03%, indicating stock-specific dynamics rather than a uniform sector move.

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	Clinical trial update	Positive	+5.7%	First‑patient‑in for Phase 1 IDE892 and broader MTAP/CDKN2A pipeline update.
Feb 27	Partner trial milestone	Positive	+2.6%	Biocytogen announced first patient dosed in IDE034 Phase 1, triggering $5M milestone.
Feb 27	Equity inducement grants	Neutral	+0.9%	Stock option inducement awards to new employees under Nasdaq Rule 5635(c)(4).
Feb 25	Clinical trial start	Positive	-1.3%	First‑patient‑in for IDE034 Phase 1 dose escalation/expansion TOP1 ADC trial.
Feb 23	Management change	Positive	+0.4%	Appointment of Dr. Theo Ross as Chief Development Officer to lead early development.

Pattern Detected

Recent IDEAYA news has generally seen positive or modestly positive price reactions, with one instance where favorable clinical news coincided with a small negative move.

Recent Company History

Over recent months, IDEAYA has reported several pipeline and corporate milestones. These include first‑patient‑in updates for IDE034 and IDE892, inducement option grants, and the appointment of a new Chief Development Officer. Most of these items, particularly clinical trial initiations, saw positive one‑day price reactions, while one IDE034 update drew a small decline. Today’s AACR presentation announcement continues this pattern of highlighting advancement across multiple first‑in‑class clinical programs.

Market Pulse Summary

This announcement highlights IDEAYA’s breadth in precision oncology, with three AACR 2026 posters co...

Analysis

This announcement highlights IDEAYA’s breadth in precision oncology, with three AACR 2026 posters covering IDE034, IDE574, and IDE892 from its clinical-stage pipeline. The company is running Phase 1 trials across multiple solid tumor types, consistent with its focus on TOP1 ADCs, DNA damage repair, and epigenetic modulation. Recent history shows steady clinical and corporate progress; investors may watch upcoming AACR data, further trial initiations, and management’s development decisions as key future markers.

Key Terms

antibody-drug conjugate, adc, phase 1, topoisomerase-1 (TOP1), +4 more

8 terms

antibody-drug conjugate medical

"topoisomerase-1 (TOP1) antibody-drug conjugate (ADC); IDE574, a potent dual"

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

adc medical

"topoisomerase-1 (TOP1) antibody-drug conjugate (ADC); IDE574, a potent dual"

An antibody-drug conjugate (ADC) is a targeted cancer medicine that pairs an antibody that recognizes specific markers on tumor cells with a potent cell-killing drug, connected so the toxic payload is delivered directly to the cancer. For investors, ADCs matter because successful ADCs can improve patient outcomes and reduce side effects compared with traditional chemotherapy, shaping clinical trial success, regulatory approval chances, commercial demand, and a company’s valuation much like a guided missile versus a general bomb.

phase 1 medical

"The company is currently conducting Phase 1 clinical studies to evaluate safety,"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

topoisomerase-1 (TOP1) medical

"PTK7/B7H3 bi-specific topoisomerase-1 (TOP1) antibody-drug conjugate (ADC);"

Topoisomerase-1 (Top1) is an enzyme that helps relieve twisting and tangling in DNA during copying and repair by making temporary cuts and then rejoining the strand—imagine a molecular seamstress unzipping and rezipping a tangled zipper so the fabric can be worked on. It matters to investors because Top1 is a proven drug target in oncology and other therapies; drugs that inhibit or trap Top1 can kill rapidly dividing cells, creating both commercial opportunities and development risks tied to efficacy, safety and resistance.

epigenetic medical

"synthetic lethality and modulation of epigenetic pathways to overcome resistance"

Epigenetic describes changes that alter how genes are turned on or off without changing the underlying DNA sequence, similar to flipping light switches or adjusting software settings that control a machine. For investors, epigenetic mechanisms matter because they create new targets for drugs, diagnostics, and therapies that can modify disease processes or patient responses, potentially leading to novel products, market opportunities, and long-term revenue streams.

prmt5 medical

"IDE892, an MTA-cooperative inhibitor of PRMT5. The company is currently"

PRMT5 is a cellular enzyme that adds small chemical tags to specific spots on other proteins, which changes how those proteins behave and how genes are read. Investors care because blocking or modifying PRMT5 can alter cell growth and survival, making it a promising drug target—especially in cancer—so clinical trial results, regulatory decisions, or biomarker developments related to PRMT5 programs can materially affect the value and risk of companies working in that space.

mtap-del medical

"optimized for development in MTAP-del cancers in combination with the allosteric"

MTAP-del denotes the loss (deletion) of the MTAP gene in a tumor, meaning the cell no longer has a working copy of that specific gene. For investors this matters because that missing gene can create a predictable weakness cancer drugs can target, much like a missing lock making a house easier to enter; therapies designed for MTAP-deleted tumors may be more effective in selected patients and can drive clinical value and commercial opportunity.

top1 adc medical

"clinical focus within TOP1 ADCs and DNA damage repair (DDR) mechanisms,"

A TOP1 ADC is an antibody-drug conjugate that uses an antibody to deliver a topoisomerase I inhibitor — a drug that blocks a cancer cell’s DNA repair machinery — directly to tumor cells. For investors, it signals a targeted cancer therapy approach that can increase effectiveness and reduce side effects compared with standard chemo, affecting clinical risk, commercial potential, and valuation like a precision-guided weapon versus a spray-and-pray treatment.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., March 18, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22 in San Diego, California. The presentations will highlight preclinical data from three potential first-in-class programs from IDEAYA's clinical stage pipeline: IDE034, a PTK7/B7H3 bi-specific topoisomerase-1 (TOP1) antibody-drug conjugate (ADC); IDE574, a potent dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7; and IDE892, an MTA-cooperative inhibitor of PRMT5. The company is currently conducting Phase 1 clinical studies to evaluate safety, tolerability, PK and efficacy of these three programs across a broad range of large solid tumor indications, including lung, colorectal, pancreatic, breast, and prostate cancer.

"We are excited for the opportunity to showcase data from our earlier stage clinical pipeline at this year's AACR. These programs align closely with our clinical focus within TOP1 ADCs and DNA damage repair (DDR) mechanisms, synthetic lethality and modulation of epigenetic pathways to overcome resistance mechanisms in cancer. Our goal is to identify first-in-class and best-in-class product profiles to deliver robust monotherapy efficacy and rational combinations that have the potential to drive deeper, more durable responses for patients living with cancer," said Michael White, Ph.D., Chief Scientific Officer of IDEAYA Biosciences.

Details of the poster presentations are as follows:

Author: Munoz Delgado, D. et al.
Title: IDE034, A bispecific antibody-drug conjugate co-targeting PTK7 and B7-H3, exhibits avidity-driven selectivity and enhanced antitumor activity versus mono-specific ADCs
Poster Number: 232
Session Title: DNA Damage and Repair 1

Date and Time: Sunday, April 19, 2026 at 2:00pm-5:00pm PDT

Author: Gupta, M. et al.
Title: The KAT6/7 inhibitor IDE574 disrupts tumor lineage identity and drug tolerance to deliver robust antitumor activity in biomarker selected indications
Poster Number: 4483
Session Title: Epigenetic Modulators 1

Date and Time: Tuesday, April 21, 2026 at 9:00am-12:00pm PDT

Author: Rao, A. et al.
Title: IDE892 is a highly potent and selective PRMT5 inhibitor, with MTA-positive and SAM-negative cooperativity, optimized for development in MTAP-del cancers in combination with the allosteric MAT2A inhibitor IDE397
Poster Number: 4505
Session Title: Epigenetic Modulators 1

Date and Time: Tuesday, April 21, 2026 at 9:00am-12:00pm PDT

The poster presentations will be made available on IDEAYA's corporate website following the meeting: https://ir.ideayabio.com/. 

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding the potential first-in-class profile, safety, tolerability, pharmacokinetics and therapeutic benefit of IDE034, IDE574 and IDE892; the potential of these programs to drive deeper, more durable responses for patients; the mechanistic rationale for targeting TOP1, DNA damage repair pathways, synthetic lethality, and epigenetic modulation; the advancement and progress of ongoing Phase 1 clinical trials; the potential for future combination strategies, including IDE892 in combination with IDE397; and the broader development strategy and clinical potential of IDEAYA's pipeline. Such forward-looking statements are based on management's current expectations, assumptions and beliefs and involve substantial risks and uncertainties that could cause actual results, including, but not limited to, those related to IDEAYA's clinical programs, commercial activities, and performance and/or achievements, to differ significantly and/or materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the process of designing and conducting preclinical and clinical trials, enrollment rates, safety outcomes, efficacy results, regulatory interactions and decisions, and the ability to translate preclinical findings into clinical benefit, manufacturing and supply risks, competition, changes in standard of care, the timing and success of commercialization efforts, the outcome of collaborations and licensing arrangements, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of financial resources to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. A further description of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, are in IDEAYA's filings with the Securities and Exchange Commission, including IDEAYA's most recent Annual Report on Form 10-K and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact

IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-upcoming-presentations-at-aacr-2026-highlighting-multiple-clinical-stage-pipeline-programs-302715276.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What is IDEAYA presenting at AACR 2026 and when will the posters be available? (IDYA)

IDEAYA is presenting three poster abstracts at AACR April 17-22, 2026 in San Diego. According to the company, posters covering IDE034, IDE574 and IDE892 will be posted on the company's investor website after the meeting for public access and review.

What programs will IDEAYA (IDYA) highlight at AACR 2026 and what are their modalities?

IDEAYA will highlight IDE034, IDE574 and IDE892, spanning an ADC, epigenetic inhibitor and PRMT5 inhibitor. According to the company, IDE034 is a PTK7/B7-H3 TOP1 bispecific ADC, IDE574 is a KAT6/7 inhibitor, and IDE892 is a PRMT5 inhibitor.

When and where is the IDE034 poster presentation at AACR 2026 (IDYA)?

The IDE034 poster is scheduled for Sunday, April 19, 2026, 2:00pm–5:00pm PDT in the DNA Damage and Repair 1 session. According to the company, poster number 232 will present preclinical data on bispecific ADC selectivity and antitumor activity.

What clinical stage and indications are IDEAYA's programs targeting as noted for AACR 2026 (IDYA)?

All three programs are in Phase 1 clinical studies evaluating safety, tolerability, PK and efficacy across large solid tumors. According to the company, indications include lung, colorectal, pancreatic, breast and prostate cancers.

What is the focus of the IDE574 poster at AACR 2026 and when is it presented (IDYA)?

The IDE574 poster will focus on KAT6/7 inhibition disrupting tumor lineage identity and drug tolerance. According to the company, poster number 4483 is scheduled for Tuesday, April 21, 2026, 9:00am–12:00pm PDT in Epigenetic Modulators 1.

How does IDE892's AACR 2026 poster describe its intended development strategy (IDYA)?

IDE892 is described as a potent, selective PRMT5 inhibitor optimized for MTAP-deleted cancers and cooperative with MAT2A inhibition. According to the company, poster number 4505 details MTA-positive and SAM-negative cooperativity and combination rationale with IDE397.